Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b randomized double-blind placebo-controlled study of ChAdOx1 Ebola BDBV vaccine in healthy adults in Uganda
PACTR202608542565174Phase 1Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ChAdOx1 Ebola BDBV vaccine in Ebola virus disease (EVD), sponsored by University of Oxford. Primary endpoints: Solicited local and systemic reactogenicity, Unsolicited adverse events and 2 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ChAdOx1 Ebola BDBV vaccine
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202608542565174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608542565174.